Researchers Match Supplement Ingredients With Foreign Prescriptions
This article was originally published in The Tan Sheet
Executive Summary
A study by researchers including Pieter Cohen, a critic of US supplement industry regulation, looks at the use of vinpocetine and picamilon in supplements and “demonstrates that some pharmaceutical drugs prescribed in other countries are sold openly in dietary supplements” in the US.
You may also be interested in...
FDA Finds Ingredient's IND Past After Signing Off For Supplement Use
Supplement industry stakeholders say FDA makes an unjustifiable regulatory move by stating that the widely used dietary supplement ingredient is noncompliant, while the finding compels the agency to reverse its earlier acceptance of NDI notifications for vinpocetine.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.